Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Maintenance Hemodialysis Clear all
Not listed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects

NCT04958187
View directory record Official record
Conditions
Hemodialysis
Interventions
ANG-3777
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Not applicable Interventional

Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

NCT00004285
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Standard dose, low flux hemodialysis, Standard dose, high flux hemodialysis, High dose, low flux hemodialysis, High dose, high flux hemodialysis
Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Sep 4, 2026, 9:37 PM EDT
Recruiting Phase 3 Interventional

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

NCT03633708
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Etelcalcetide, Standard of Care
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Kansas City, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis

NCT03301740
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UF profiling during HD, Conventional HD
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Carrboro, North Carolina • Siler City, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT02064426
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Azusa, California • Long Beach, California • Lynwood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 4, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

A Safety Study of Pentoxifylline for the Treatment of Anemia

NCT01102218
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Erythropoietin, Pentoxifylline
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Chicago, Illinois • Kalamazoo, Michigan • Brookhaven, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Peginesatide for Anemia in Chronic Hemodialysis Patients

NCT00228449
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Chronic Renal Failure
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 3 Interventional

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

NCT00561093
View directory record Official record
Conditions
Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions
pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
Drug · Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Irvine, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Sep 4, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD

NCT00372489
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
9
States / cities
Pine Bluff, Arkansas • Mountain View, California • Lauderdale Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597753
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin Alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
89
States / cities
Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Not applicable Interventional

The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis

NCT03943212
View directory record Official record
Conditions
ESRD, Fatigue, Hemodialysis-Induced Symptom
Interventions
Blood Flow Rate Reduction, Control
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years to 89 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
18
States / cities
Capitola, California • Daly City, California • Gilroy, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis

NCT04571619
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Pain, Opioid Dependence
Interventions
Pain Coping Skills Training (PCST), Buprenorphine
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
West Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153
View directory record Official record
Conditions
Anemia
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease (CKD)
Interventions
Vadadustat, Mircera®
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
58
States / cities
Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 4, 2026, 9:37 PM EDT
Completed No phase listed Observational

Prevalence of Metabolic Syndrome in a Maintenance Hemodialysis Population

NCT01176630
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Winthrop University Hospital
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis

NCT02289703
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Rivaroxaban 15 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

Peer Mentorship to Improve Outcomes in Patients on Maintenance Hemodialysis

NCT03595748
View directory record Official record
Conditions
Dialysis
Interventions
Peer mentorship
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
The Bronx, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis

NCT03534284
View directory record Official record
Conditions
Insomnia, End Stage Renal Disease
Interventions
Cognitive Behavioral Therapy for Insomnia, Trazodone, Placebo
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

NCT02273726
View directory record Official record
Conditions
CKD Anemia in Stable Dialysis Patients
Interventions
Epoetin Alfa, Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
74
States / cities
Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Not applicable Interventional

Dietary Protein Requirements in Hemodialysis Patients

NCT02194114
View directory record Official record
Conditions
Chronic Renal Failure, End-Stage Renal Disease
Interventions
Protein Diet
Other
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
25 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

NCT00048035
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

NCT01286012
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Soluble Ferric Pyrophosphate in liquid bicarbonate, Placebo: Conventional liquid bicarbonate, Erythrocyte Stimulating Agent (ESA), Intravenous (IV) Iron
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Tempe, Arizona • Granada Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2018 · Synced Sep 4, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

Gut Microbiome and p-Inulin in Hemodialysis

NCT02572882
View directory record Official record
Conditions
End-Stage Renal Disease, Gut Microbiome Dysbiosis
Interventions
p-inulin
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 4, 2026, 9:37 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Hypoxemia in Maintenance Hemodialysis Patients

NCT03045796
View directory record Official record
Conditions
Oxygen Saturation and the Relationship to Other Cardiac Variables, Maintenance Hemodialysis, Kidney Failure, Chronic
Interventions
Oxygen Saturation measured by WristOx
Device
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 4, 2026, 9:37 PM EDT